C07K 14/70525
Icam molecules
Official title: {ICAM molecules, e.g. CD50, CD54, CD102}
C07K14/70525 (Icam molecules) appears on 115 US grants and 77 published applications in this corpus.
Search patents in C07K- Granted patents
- 115
- Published applications
- 77
- Assignees
- 73
- Inventors
- 236
- Latest grant
- 3 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 1 | 0 |
| 1996 | 7 | 0 |
| 1997 | 12 | 0 |
| 1998 | 17 | 0 |
| 1999 | 14 | 0 |
| 2000 | 10 | 0 |
| 2001 | 5 | 1 |
| 2002 | 4 | 5 |
| 2003 | 4 | 10 |
| 2004 | 8 | 5 |
| 2005 | 2 | 2 |
| 2006 | 3 | 3 |
| 2007 | 1 | 2 |
| 2008 | 4 | 1 |
| 2009 | 0 | 3 |
| 2010 | 2 | 2 |
| 2011 | 1 | 0 |
| 2012 | 0 | 1 |
| 2013 | 1 | 1 |
| 2014 | 1 | 0 |
| 2015 | 0 | 2 |
| 2016 | 0 | 1 |
| 2017 | 1 | 3 |
| 2018 | 0 | 0 |
| 2019 | 1 | 4 |
| 2020 | 0 | 3 |
| 2021 | 1 | 5 |
| 2022 | 5 | 6 |
| 2023 | 2 | 3 |
| 2024 | 2 | 4 |
| 2025 | 1 | 5 |
| 2026 | 1 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for treating cancer with anti-ROR1 immunotherapy3 Feb 2026US 12,540,179 B2Lentigen Technology, Inc.
- ICAM-1 targeted fusion enzymes3 Jun 2025US 12,319,719 B2University of Maryland, College Park
- Methods and compositions for natural killer cells27 Aug 2024US 12,070,474 B2University of Central Florida Research Foundation, Inc.
- ICAM-1 targeted fusion enzymes27 Feb 2024US 11,912,745 B2University of Maryland, College Park
- Pharmaceutical chimeric receptor composition and method thereof13 Jun 2023US 11,672,827 B2
- Material and Methods for Improved Bioengineered Pairing of Antigen-Binding Variable Regions3 Sep 2026US 2026/0258158 A1Janssen Biotech, Inc.
- Monobodies binding to intercellular adhesion molecule 2 (icam-2)27 Aug 2026US 2026/0250391 A1
- Engineered cells and methods of use30 Jul 2026US 2026/0216329 A1
- Engineered cells for the production of cd4+ t cells and cd4+ tregs23 Jul 2026US 2026/0209699 A1BlueRock Therapeutics LP
- Adhesion molecule inhibition for stem cell therapies7 May 2026US 2026/0124246 A1Wisconsin Alumni Research Foundation
Most cited
By later US patents
- Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations127US 6,391,452 B1Bayer Aktiengesellschaft · 2002
- Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2109US 5,789,573 AIsis Pharmaceuticals, Inc. · 1998
- Oligonucleotide modulation of cell adhesion96US 5,514,788 AIsis Pharmaceuticals, Inc. · 1996
- Intercellular adhesion molecules, and their binding ligands66US 5,284,931 ADana-Farber Cancer Institute, Inc. · 1994
- Oligonucleotide modulation of cell adhesion60US 5,591,623 AIsis Pharmaceuticals, Inc. · 1997